Findings
D + Q reduced adipose tissue senescent cell burden within 11 days, with decreases in p16INK4A-and p21CIP1-expressing cells, cells with senescence-associated β-galactosidase activity, and adipocyte progenitors with limited replicative potential. Adipose tissue macrophages, which are attracted, anchored, and activated by senescent cells, and crown-like structures were decreased. Skin epidermal p16INK4A+ and p21CIP1+ cells were reduced, as were circulating SASP factors, including IL-1α, IL-6, and MMPs-9 and −12.
Interpretation
“Hit-and-run” treatment with senolytics, which in the case of D + Q have elimination half-lives <11 h, significantly decreases senescent cell burden in humans.
https://www.sciencedirect.com/science/a ... 6419305912
Senolytics ⇒ Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin
Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin
Ph.D. student at Harvard Medical School, doing research on aging
Re: Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin
When I looked into this combination 6 months ago Dasatinib was difficult to get. It's basically a Chemotherapy treatment for leukemia. Quercetin is not a very effective senolytic on its own, but even in combination this is not as effective as Fisetin. I guess the only question would be does it kill different types of senescent cells than Fisetin, so that alternating this combination with Fisetin would kill the broadest range of senescent cells? How long before they come up with a powerful prescription senolytic?